Structure-based drug design and biological evaluation of 2-acetamidobenzothiazole derivative as EGFR kinase inhibitor

Area of Science:

• Oncology
• Medicinal Chemistry
• Pharmacology

Background:

• Epidermal Growth Factor Receptor (EGFR) tyrosine kinase is a key target in non-small cell lung cancer (NSCLC), colon, and breast cancers, often overexpressed.
• Targeting EGFR is a validated strategy for cancer therapy, with existing drugs like erlotinib showing clinical benefit.
• Development of novel, more potent EGFR inhibitors is crucial for overcoming resistance and improving treatment outcomes.

Purpose of the Study:

• To synthesize and evaluate a novel, highly potent antitumor agent.
• To assess the compound's efficacy against various cancer cell lines, including NSCLC, colon, and breast cancer.
• To investigate the compound's inhibitory activity against EGFR kinase and other kinases, and evaluate its in vivo toxicity.

Main Methods:

• Chemical synthesis of compound 4.
• In vitro screening of compound 4 against NSCLC, colon, and breast cancer cell lines.
• Enzymatic kinase inhibition assays at a single dose (100 µM) against 11 kinases.
• Determination of IC50 values for EGFR kinase inhibition in a 10-dose mode.
• In vivo acute toxicity testing.

Main Results:

• Compound 4 exhibited potent antitumor activity against tested cancer cell lines, outperforming erlotinib against NSCLC and colon cancer lines.
• Compound 4 demonstrated significant EGFR kinase inhibition (94.45% at 100 µM) with high selectivity over other kinases (inhibition <55%).
• The IC50 value for compound 4 against EGFR kinase was determined to be 0.239 µM, indicating high potency.

Conclusions:

• Compound 4 represents a highly potent and selective EGFR kinase inhibitor with significant antitumor potential.
• The synthesized compound shows promise as a next-generation therapeutic agent for EGFR-driven cancers.
• Further preclinical and clinical investigations are warranted to establish the therapeutic utility of compound 4.